Literature DB >> 29207000

Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Countries.

Carole L Wallis1, Catherine Godfrey2, Joseph E Fitzgibbon3, John W Mellors2,4.   

Abstract

The emergence and spread of human immunodeficiency virus (HIV) drug resistance from antiretroviral roll-out programs remain a threat to long-term control of the HIV-AIDS epidemic in low- and middle-income countries (LMICs). The patterns of drug resistance and factors driving emergence of resistance are complex and multifactorial. The key drivers of drug resistance in LMICs are reviewed here, and recommendations are made to limit their influence on antiretroviral therapy efficacy.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV subtype; HIV-1 drug resistance; antiretroviral therapy failure

Mesh：

Substances：

Year:  2017        PMID： 29207000      PMCID： PMC5853971          DOI： 10.1093/infdis/jix409

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  58 in total

1.  HIV drug resistance mutations among patients failing second-line antiretroviral therapy in Rwanda.

Authors:  Jean d'Amour Ndahimana; David J Riedel; Ribakare Muhayimpundu; Sabin Nsanzimana; Gad Niyibizi; Emmanuel Mutaganzwa; Augustin Mulindabigwi; Cyprien Baribwira; Athanase Kiromera; Linda L Jagodzinski; Sheila A Peel; Robert R Redfield
Journal:  Antivir Ther       Date:  2015-11-12

2.  Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial.

Authors:  P M Girard; A Antinori; J R Arribas; D Ripamonti; C Bicer; B Netzle-Sveine; B Hadacek; C Moecklinghoff
Journal:  HIV Med       Date:  2016-06-09       Impact factor: 3.180

3.  Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.

Authors:  Michele W Tang; Soo-Yon Rhee; Silvia Bertagnolio; Nathan Ford; Susan Holmes; Kim C Sigaloff; Raph L Hamers; Tobias F Rinke de Wit; Herve J Fleury; Phyllis J Kanki; Kiat Ruxrungtham; Claudia A Hawkins; Carole L Wallis; Wendy Stevens; Gert U van Zyl; Weerawat Manosuthi; Mina C Hosseinipour; Nicole Ngo-Giang-Huong; Laurent Belec; Martine Peeters; Avelin Aghokeng; Torsak Bunupuradah; Sherri Burda; Patricia Cane; Giulia Cappelli; Charlotte Charpentier; Anoumou Y Dagnra; Alaka K Deshpande; Ziad El-Katib; Susan H Eshleman; Joseph Fokam; Jean-Chrysostome Gody; David Katzenstein; Donato D Koyalta; Johnstone J Kumwenda; Marc Lallemant; Lutgarde Lynen; Vincent C Marconi; Nicolas A Margot; Sandrine Moussa; Thumbi Ndung'u; Phillipe N Nyambi; Catherine Orrell; Jonathan M Schapiro; Rob Schuurman; Sunee Sirivichayakul; Davey Smith; Maria Zolfo; Michael R Jordan; Robert W Shafer
Journal:  J Infect Dis       Date:  2013-06-15       Impact factor: 5.226

4.  Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine.

Authors:  Valerie F Boltz; Yu Zheng; Shahin Lockman; Feiyu Hong; Elias K Halvas; James McIntyre; Judith S Currier; Margret C Chibowa; Cecelia Kanyama; Apsara Nair; Willis Owino-Ong'or; Michael Hughes; John M Coffin; John W Mellors
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-16       Impact factor: 11.205

5.  HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.

Authors:  Raph L Hamers; Carole L Wallis; Cissy Kityo; Margaret Siwale; Kishor Mandaliya; Francesca Conradie; Mariette E Botes; Maureen Wellington; Akin Osibogun; Kim C E Sigaloff; Immaculate Nankya; Rob Schuurman; Ferdinand W Wit; Wendy S Stevens; Michèle van Vugt; Tobias F Rinke de Wit
Journal:  Lancet Infect Dis       Date:  2011-07-27       Impact factor: 25.071

6.  Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine.

Authors:  Lynn Morris; Candice Pillay; Claudia Chezzi; Pumla Lupondwana; Matshediso Ntsala; Leon Levin; Francois Venter; Neil Martinson; Glenda Gray; James McIntyre
Journal:  AIDS       Date:  2003-07-25       Impact factor: 4.177

7.  HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme.

Authors:  Catherine Orrell; Rochelle P Walensky; Elena Losina; Jennifer Pitt; Kenneth A Freedberg; Robin Wood
Journal:  Antivir Ther       Date:  2009

8.  Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa.

Authors:  Carole L Wallis; John W Mellors; Willem D F Venter; Ian Sanne; Wendy Stevens
Journal:  AIDS Res Treat       Date:  2010-12-02

Review 9.  The Effect on Treatment Adherence of Administering Drugs as Fixed-Dose Combinations versus as Separate Pills: Systematic Review and Meta-Analysis.

Authors:  Katy A van Galen; Jeannine F Nellen; Pythia T Nieuwkerk
Journal:  AIDS Res Treat       Date:  2014-09-04

10.  HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir.

Authors:  K A Sutherland; J Ghosn; J Gregson; J L Mbisa; M L Chaix; I Cohen Codar; J F Delfraissy; C Delaugerre; R K Gupta
Journal:  J Antimicrob Chemother       Date:  2014-09-16       Impact factor: 5.790
View more
  13 in total

Review 1.  Scientific considerations for global drug development.

Authors:  Jennifer L Wilson; Kit Wun Kathy Cheung; Lawrence Lin; Elizabeth A E Green; Analia I Porrás; Ling Zou; David Mukanga; Paul A Akpa; Delese Mimi Darko; Rae Yuan; Sheng Ding; Wiltshire C N Johnson; Howard A Lee; Emer Cooke; Carl C Peck; Steven E Kern; Dan Hartman; Yoshikazu Hayashi; Peter W Marks; Russ B Altman; Murray M Lumpkin; Kathleen M Giacomini; Terrence F Blaschke
Journal:  Sci Transl Med       Date:  2020-07-29       Impact factor: 17.956

2.  Linked dual-class HIV resistance mutations are associated with treatment failure.

Authors:  Valerie F Boltz; Wei Shao; Michael J Bale; Elias K Halvas; Brian Luke; James A McIntyre; Robert T Schooley; Shahin Lockman; Judith S Currier; Fred Sawe; Evelyn Hogg; Michael D Hughes; Mary F Kearney; John M Coffin; John W Mellors
Journal:  JCI Insight       Date:  2019-10-03

3.  Four-class drug-resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir-based antiretroviral therapy in Botswana.

Authors:  Kaelo K Seatla; Ava Avalos; Sikhulile Moyo; Madisa Mine; Thabo Diphoko; Mosepele Mosepele; Tendani Gaolatlhe; Christopher F Rowley; Dinah Ramaabya; Joseph N Jarvis; Ishmael Kasvosve; Simani Gaseitsiwe
Journal:  AIDS       Date:  2018-08-24       Impact factor: 4.177

4.  Antimicrobial Resistance and Substandard and Falsified Medicines: The Case of HIV/AIDS.

Authors:  Amitabh B Suthar; William Coggin; Elliot Raizes
Journal:  J Infect Dis       Date:  2019-01-29       Impact factor: 5.226

5.  Towards the third 90: improving viral load testing with a simple quality improvement program in health facilities in Malawi.

Authors:  Julie Hubbard; Gift Kakwesa; Mike Nyirenda; James Mwambene; Ashley Bardon; Kelvin Balakasi; Kathryn Dovel; Thokozani Kalua; Risa M Hoffman
Journal:  Int Health       Date:  2019-05-01       Impact factor: 2.473

6.  Dolutegravir Monotherapy of Simian Immunodeficiency Virus-Infected Macaques Selects for Several Patterns of Resistance Mutations with Variable Virological Outcomes.

Authors:  Koen K A Van Rompay; Said Hassounah; Brandon F Keele; Jeffrey D Lifson; Amir Ardeshir; Jennifer Watanabe; Hanh Thi Pham; Elena Chertova; Raymond Sowder; Jan Balzarini; Thibault Mesplède; Mark A Wainberg
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

7.  Diverse Human Immunodeficiency Virus-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited Settings.

Authors:  Carole L Wallis; Michael D Hughes; Justin Ritz; Raquel Viana; Carlos Silva de Jesus; Shanmugam Saravanan; Marije van Schalkwyk; Rosie Mngqibisa; Robert Salata; Peter Mugyenyi; Evelyn Hogg; Laura Hovind; Linda Wieclaw; Robert Gross; Catherine Godfrey; Ann C Collier; Beatriz Grinsztejn; John W Mellors
Journal:  Clin Infect Dis       Date:  2020-10-23       Impact factor: 20.999

8.  A case report of untreatable HIV infection in Harare, Zimbabwe.

Authors:  Cleophas Chimbetete; Linda Chirimuta; Margaret Pascoe; Olivia Keiser
Journal:  South Afr J HIV Med       Date:  2019-06-27       Impact factor: 2.744

9.  Prevalence of HIV-1 pretreatment drug resistance among treatment naïve pregnant women in Bissau, Guinea Bissau.

Authors:  Sten Wilhelmson; Fredrik Månsson; Jacob Lopatko Lindman; Ansu Biai; Joakim Esbjörnsson; Hans Norrgren; Marianne Jansson; Patrik Medstrand
Journal:  PLoS One       Date:  2018-10-31       Impact factor: 3.240

10.  HIV-genetic diversity and drug resistance transmission clusters in Gondar, Northern Ethiopia, 2003-2013.

Authors:  Dawit Assefa Arimide; Almaz Abebe; Yenew Kebede; Fekadu Adugna; Tesfaye Tilahun; Desta Kassa; Yibeltal Assefa; Taye Tolera Balcha; Per Björkman; Patrik Medstrand
Journal:  PLoS One       Date:  2018-10-10       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.